ICIs are monoclonal antibodies that restore the immune response of T cells to tumor tissues by blocking programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-cell lymphocyte antigen-4. This evidence concerns the gene CD274 and neoplasm.